|
| |
chemocentryx Pages on BioPortfolio:
BioPortfolio - ChemoCentryx, Inc.
ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
ChemoCentryx Advances Second Orally Available CCR9 Antagonist ...
Pharma Live:
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...
|
BioPortfolio - BioPortfolio - ChemoCentryx, Inc.
BioPortfolio - ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/linkout/20818/www.c...
|
BioPortfolio - ChemoCentryx - Profile
View the current ChemoCentryx Page on BioPortfolio.com ... ChemoCentryx is a privately held biopharma company specializing in the biology of chemokines, ...
http://www.bioportfolio.com/biocorporate/2673-ChemoCentryx.p...
|
BioPortfolio - ChemoCentryx, Inc. - Profile
View the current ChemoCentryx, Inc. Page on BioPortfolio.com ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available ...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
BioPortfolio - amgen chemocentryx
amgen chemocentryx - BioPortfolio. ... Recent Search Terms used to find this page: amgen chemocentryx | chemocentryx . ...
http://www.bioportfolio.com/search/amgen_chemocentryx.html...
|
BioPortfolio - chemocentryx
BioPortfolio - ChemoCentryx - Entry on Bioportfolio's Biocorporate Database. ... ChemoCentryx Advances Second Orally Available CCR9 Antagonist . ...
http://www.bioportfolio.com/search/chemocentryx_.html...
|
Solexa Names Linda Rubinstein Vice President And CFO
Among her responsibilities at ChemoCentryx, she served on the executive and ... Prior to joining ChemoCentryx, Ms. Rubinstein was senior vice president in ...
http://www.bioportfolio.com/news/solexa_12.htm...
|
BioPortfolio - CCR2
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, ...
http://www.bioportfolio.com/indepth/CCR2.html...
|
BioPortfolio - Biocorporate Search Molecular Biology
ChemoCentryx is a privately held biopharma company specializing in the biology of chemokines, protein hormones that regulate the migration, or trafficking, ...
http://www.bioportfolio.com/biocorporate/Molecular%20Biology...
|
Results from other life science and pharmaceutical sites:
BioSpace - ChemoCentryx, Inc. News, Search Jobs, Events
ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for
...
http://www.biospace.com/company_profile.aspx?CompanyId=13520...
|
GlaxoSmithKline and ChemoCentryx enter into drug discovery and ...
GlaxoSmithKline(GSK) and ChemoCentryx Inc. today announced a worldwide multi- target ... In addition, ChemoCentryx will receive research funding and will be
...
http://www.gsk.com/media/pressreleases/2006/2006_08_24_GSK87...
|
ChemoCentryx, Inc. Cancels IPO - News, Search Jobs, Events
17 Nov 2008 ... PeHUB -- ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and ...
http://www.biospace.com/news_story.aspx?StoryID=117701&full=...
|
ChemoCentryx Advances Second Orally Available CCR9 Antagonist ...
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development. - MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ ...
http://biz.yahoo.com/prnews/081015/aqw521a.html?.v=1...
|
BioPortfolio - ChemoCentryx, Inc.
ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor ...
CXCR7 is a novel chemokine receptor whose function was discovered and characterized by ChemoCentryx. ChemoCentryx scientists, joined by researchers
from the ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
BioPortfolio - ChemoCentryx - Profile
View the current ChemoCentryx Page on BioPortfolio.com ... ChemoCentryx is a privately held biopharma company specializing in the biology of chemokines, ...
http://www.bioportfolio.com/biocorporate/2673-ChemoCentryx.p...
|
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline ...
The milestone payment was triggered by the acceptance of ChemoCentryx' orally bioavailable small molecule, CCX354, as a candidate for full development. ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
ChemoCentryx, Inc.'s Traficet-EN(R) Phase 2 Data in Crohn's ...
23 May 2007 ... Wednesday, May 23, 2007 at 4:45 p.m. Room 207 Detailed results from ChemoCentryx's Phase 2 randomized clinical trial will be provided in an ...
http://www.biospace.com/news_story.aspx?NewsEntityId=56920...
|
Chemocentryx
08:30 ET, ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III ... 08: 00 ET, ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 ...
http://www.prnewswire.com/gh/cnoc/comp/156506.html...
|
|
